

PRESS RELEASE

Lund, Sweden - 6 September 2010



HANSA MEDICAL AB ENTERS LICENSE AGREEMENT WITH HUMAN GENOME SCIENCES INC.

Hansa Medical AB (NASDAQ OMX First North:HMED) today announced that they have entered a license agreement with Human Genome Sciences Inc. (NASDAQ:HGSI) regarding patents and patent applications around the drug target alpha-11.

The license agreement gives Hansa Medical an exclusive and global right to HGSIs all granted patents and pending patent applications regarding inventions around the alpha-11 integrin such as therapeutic anti-alpha-11 antibodies. Specific terms of the agreement were not disclosed.

“By uniting Hansa Medicals’ alpha-11 patent applications with the patents around alpha-11 developed by Human Genome Sciences, we create a strong patent portfolio for our anti-alpha-11 program. Integrating all intellectual property around the alpha-11 protein in one portfolio will further increase the commercial potential for this novel and innovative drug target” says Emanuel Björne, Chief Executive Officer of Hansa Medical

Alpha-11 is a novel drug target for treatment of the autoimmune disease rheumatoid arthritis. In research studies, Hansa Medical have shown that anti-alpha-11 antibodies potentially could have better efficacy profile than present treatments on the market today. The market for biological treatments of reumatoid arthritis is estimated to be approximately USD 12 billion in 2010.

For further information, please contact:

Hansa Medical AB
Emanuel Björne, CEO
Phone: +46 707 175477
E-mail: emanuel.bjorne@hansamedical.com

ABOUT HANSA MEDICAL

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops three product candidates in preclinical or early clinical phase; IdeS, anti-alpha-11 and HMD-301. IdeS is a novel treatment prior to organ transplantation. Anti-alpha-11 is a more specific rheumatoid arthritis treatment. HMD-301 is a novel diagnostic method for diagnosis and prognosis of severe sepsis. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund
Phone +46 46 16 56 70
Fax +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund, SWEDEN